GlassScriptPhysician profile
James Kent
NPI 1912356536
$8,491.37
in general payments reported to CMS, 2019-2025
33 companies · $1,711 in 2025
The $1,711 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,709 · 2022: $1,485 · 2023: $1,465 · 2024: $2,120 · 2025: $1,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,296.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,550.03 | 2021-2025 | Wegovy, Ozempic, Saxenda |
| Abbvie INC. | $1,512.53 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $747.67 | 2021-2025 | Rexulti |
| Esperion Therapeutics, INC. | $598.07 | 2021-2022 | |
| Pfizer INC. | $593.57 | 2021-2025 | |
| Astellas Pharma US INC | $467.83 | 2021-2025 | Veozah, Myrbetriq |
| Amgen INC. | $458.14 | 2021-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $399.76 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $353.12 | 2021-2025 | Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $282.45 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $231.16 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Axsome Therapeutics, INC. | $217.37 | 2025 | Auvelity, Symbravo |
| Boston Scientific Corporation | $192.92 | 2022-2025 | Bulkamid - Bulkamid Urethral Bulking Pack 2ml (Ous), Upsylon |
| Exact Sciences Corporation | $180.46 | 2023-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $80.98 | 2021-2025 | Heplisav-B |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $66.87 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.57 | 2021-2024 | Jardiance, Synjardy, Ofev |
| Astrazeneca Pharmaceuticals LP | $59.03 | 2022-2025 | Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.74 | 2025 | Caplyta |
| Eisai INC. | $53.43 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.89 | 2021-2023 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $44.80 | 2025 | Voquezna |
| Amarin Pharma, INC. | $43.91 | 2021 | |
| Medtronic, INC. | $27.42 | 2025 | Intellis Adaptivestim |
| Inspire Medical Systems, INC. | $23.68 | 2023 | Inspire |
| Dexcom, INC. | $20.89 | 2021 | |
| Daiichi Sankyo INC. | $20.81 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.27 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.54 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.46 | 2023 | Livalo |
| Janssen Pharmaceuticals, INC | $13.92 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.75 | 2021 | |
| Corcept Therapeutics | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.